Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II induction erlotinib followed by surgery in stage IIIA-N2 EGFR-mutant non-small cell lung cancer
jRCTs031180404Phase 2Active, not recruiting
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC) and bronchial carcinoma. Primary endpoint: 2-year progression-free survival. Started Aug 2017; status: active, not recruiting.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on jRCTs031180404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180404.